Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02714764 · ClinicalTrials.gov registry record

Evaluation of Outcome Metrics in Alexander Disease

A clinical trial of Alexander Disease, sponsored by Children's Hospital of Philadelphia.

Recruiting
Registry status
200
Enrollment target
1
Study location

NCT02714764 is a study of Alexander Disease that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 200 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02714764, a study of Alexander Disease, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.

RECRUITING
Registry status
200 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to define the natural history of Alexander Disease, a leukodystrophy that causes neurological dysfunction. Investigators will obtain clinical outcome assessments to measure how the disease affects a patient's gross motor, fine motor, speech and language function, swallowing, and quality of life. Specimens are collected to measure glial fibrillary acidic protein (GFAP) levels in cerebrospinal fluid (CSF) and blood. The data obtained from this study will be used for the design of future treatment trials.

Conditions Studied

Study Locations (1)

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2016-01-26
Est. Completion 2030-12

Sponsor

Children's Hospital of Philadelphia

431 total trials

What the Registry Record Tells You About NCT02714764

The ClinicalTrials.gov registry entry for NCT02714764 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital of Philadelphia, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alexander Disease appearing as the primary indexed condition, and to 0 interventions.

NCT02714764 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02714764 about?

NCT02714764 is a clinical study titled "Evaluation of Outcome Metrics in Alexander Disease". The purpose of this study is to define the natural history of Alexander Disease, a leukodystrophy that causes neurological dysfunction. Investigators will obtain clinical outcome assessments to measure how the disease affects a patient's gross motor, fine motor, speech and language function, swallow...

What is the current status of trial NCT02714764?

This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2016-01-26. Estimated completion is 2030-12.

What conditions does trial NCT02714764 study?

This clinical trial studies the following conditions: Alexander Disease.

Who is sponsoring clinical trial NCT02714764?

This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02714764 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alexander Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.